The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts

Blood

Volumn 121, Issue 22, 2013, Pages 4439-4442

  Abboud, Camille ^a   Berman, Ellin ^a   Cohen, Adam ^a   Cortes, Jorge ^a   DeAngelo, Daniel ^a   Deininger, Michael ^a   Devine, Steven ^a   Druker, Brian ^a   Fathi, Amir ^a   Jabbour, Elias ^a   Jagasia, Madan ^a   Kantarjian, Hagop ^a   Khoury, Jean ^a   Laneuville, Pierre ^a   Larson, Richard ^a   Lipton, Jeffrey ^a   Moore, Joseph O ^a   Mughal, Tariq ^a   O'Brien, Susan ^a   Pinilla Ibarz, Javier ^a   Quintas Cardama, Alfonso ^a   Radich, Jerald ^a   Reddy, Vishnu ^a   Schiffer, Charles ^a   Shah, Neil ^a   Shami, Paul ^a   Silver, Richard T ^a   Snyder, David ^a   Stone, Richard ^a   Talpaz, Moshe ^a   Tefferi, Ayalew ^a   Van Etten, Richard A ^a   Wetzler, Meir ^a   Abruzzese, Elisabetta ^a   Apperley, Jane ^a   Breccia, Massimo ^a   Byrne, Jenny ^a   Cervantes, Francisco ^a   Chelysheva, Ekaterina ^a   Clark, R E ^a   De Lavallade, Hugues ^a   Dyagil, Iryna ^a   Gambacorti Passerini, Carlo ^a   Goldman, John ^a   Haznedaroglu, Ibrahim ^a   Hjorth Hansen, Henrik ^a   Holyoake, Tessa ^a   Huntly, Brian ^a   Le Coutre, Philipp ^a   Lomaia, Elza ^a   Mahon, Francois Xavier ^a   Marin Costa, David ^a   Martinelli, Giovanni ^a   Mayer, Jiri ^a   Milojkovic, Dragana ^a   Olavarria, Eduardo ^a   Porkka, Kimmo ^a   Richter, Johan ^a   Rousselot, Philippe ^a   Saglio, Giuseppe ^a   Saydam, Guray ^a   Stentoft, Jesper ^a   Turkina, Anna ^a   Vigneri, Paolo ^a   Zaritskey, Andrey ^a   Aguayo, Alvaro ^a   Ayala, Manuel ^a   Bendit, Israel ^a   Bengio, Raquel Maria ^a   Best, Carlos ^a   Bullorsky, Eduardo ^a   Cervera, Eduardo ^a   Desouza, Carmino ^a   Fanilla, Ernesto ^a   Gomez Almaguer, David ^a   Hamerschlak, Nelson ^a   Lopez, Jose ^a   Magarinos, Alicia ^a   Meillon, Luis ^a   Milone, Jorge ^a   Moiraghi, Beatriz ^a   Pasquini, Ricardo ^a   Pavlovsky, Carolina ^a   Ruiz Arguelles, Guillermo J ^a   Spector, Nelson ^a   Arthur, Christopher ^a   Browett, Peter ^a   Grigg, Andrew ^a   Hu, Jianda ^a   Huang, Xiao jun ^a   Hughes, Tim ^a   Jiang, Qian ^a   Jootar, Saengsuree ^a   Kim, Dong Wook ^a   Malhotra, Hemant ^a   Malhotra, Pankaj ^a   Matsumura, Itaru ^a   Melo, Junia ^a   Ohnishi, Kazunori ^a   Ohno, Ryuzo ^a   Saikia, Tapan ^a   Schwarer, Anthony P ^a   Takahashi, Naoto ^a   Tam, Constantine ^a   Tauchi, Tetsuzo ^a   Usuki, Kensuke ^a   Wang, Jianxiang ^a   Abdel Rahman, Fawzi ^a   Aljurf, Mahmoud Deeb Saeed ^a   Bazarba Chi, Ali ^a   Yehuda, Dina Ben ^a   Chaudhri, Naeem ^a   Durosinmi, Muheez ^a   Kamel, Hossam ^a   Louw, Vernon ^a   Matti, Bassam Francis ^a   Nagler, Arnon ^a   Raanani, Pia ^a   Salem, Ziad ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; DASATINIB; IMATINIB; NILOTINIB; ANTINEOPLASTIC AGENT; GENERIC DRUG;

ARTICLE; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; EUROPE; HEALTH CARE POLICY; HUMAN; LONG TERM SURVIVAL; PATENT; PRIORITY JOURNAL; SOUTH KOREA; UNITED STATES; ECONOMICS;

ANTINEOPLASTIC AGENTS; DRUG COSTS; DRUG INDUSTRY; DRUGS, GENERIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PATENTS AS TOPIC;

EID: 84880790088     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-490003     Document Type: Article

References (26)

1. Red Book online database. Accessed February 20, 2013.
2. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2009; 101(15):1044-1048.
3. Goozer M. The $800 Million Pill: The Truth Behind the Cost of New Drugs. Berkley, CA: University of California Press; 2004.
4. Light DW, Lexchin JR. Pharmaceutical research and development: what do we get for all that money? BMJ. 2012;345:e4348.
5. Vasella D. Magic Cancer Bullet: How a Tiny Orange Pill Is Rewriting Medical History. New York, NY: Harper Collins Publishers; 2003: 15-18,126,160-163,171-181.
6. Lee CP, Chertow GM, Zenios SA. An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health. 2009;12(1):80-87.
7. Rascati KL. The $64,000 question—what is a quality-adjusted life-year worth? Clin Ther. 2006;28(7):1042-1043.
8. Kantarjian H, O’Brien S. The chronic leukemias. In: Goldman L, Schafer A, Arend W, et al, eds. Cecil Medicine. 24 ed. Philadelphia, PA: Elsevier Saunders; 2012:1209-1218.
9. Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011; 103(7):553-561.
10. Himmelstein DU, Thorne D, Warren E, Woolhandler S. Medical bankruptcy in the United States, 2007: results of a national study. Am J Med. 2009;122(8):741-746.
11. Bundesministerium für Gesundheit. The act on the reform on the market for medicinal products (Gesetz zur Neuordnung des Arzneimittelmarktes - AMNOG). http://www.bmg.bund.de/ministerium/english-version/amnog.html. Accessed February 20, 2013.
12. The Pharma Letter. German pharma criticizes new AMNOG vetting procedure. March 2012. http://www.thepharmaletter.com/file/111771/ german-pharma-criticizes-new-amnog-vetting-procedure.html. Accessed February 20, 2013.
13. Centers for Medicare & Medicaid Services. National Health Expenditure Projections 2011-2021. http://www.cms.gov/Research-StatisticsData-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/ Proj2011PDF.pdf. Accessed October 2012.
14. Himmelstein DU, Woolhandler S. Cost control in a parallel universe: Medicare spending in the United States and Canada. Arch Intern Med. 2012;172(22):1764-1766.
15. Ruiz-Argüelles GJ, Tarin-Arzaga LC, Gonzalez-Carrillo ML, et al. Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs? Bone Marrow Transplant. 2008;42(1):23-28.
16. Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012;118(12): 3123-3127.
17. Silverman E. Petition demands Novartis lower US Gleevec price. http://www.pharmalot.com/2012/05/petition-demands-novartis-lower-us-gleevec-price/. Accessed February 20, 2013.
18. Health Watched. US patient petition calling for reduction of Gleevec price. http://healthwatched. org/2012/05/09/us-patient-petition-calling-for-reduction-of-gleevec-price/. Accessed February 20, 2013.
19. Hillner BE, Smith TJ. Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. J Clin Oncol. 2009; 27(13):2111-2113.
20. Stiglitz J. The Price of Inequality. New York, NY: W.W. Norton and Company, Inc.; 2012:45.
21. The Max Foundation. Glivec International Patient Assistance Program (GIPAP). http://www.themaxfoundation.org/gipap/Default.aspx. Accessed February 20, 2013.
22. Björkholm M, Ohm L, Eloranta S, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011;29(18): 2514-2520.
23. The Economist. The costly war on cancer. New cancer drugs are technically impressive. But must they cost so much? May 26, 2011. http://www.economist.com/node/18743951. Accessed February 20, 2013.
24. Chen Y, Wang H, Kantarjian H, Cortes J. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009 [published online ahead of print December 5, 2012]. Leuk Lymphoma. doi: 10.3109/10428194.2012.745525.
25. Wyatt E. Justices to take up generic drug case. The New York Times. December 8, 2012;B1.
26. Federal Trade Commission. Authorized generic drugs: short-term effects and long-term impact. http://www.ftc.gov/os/2011/08/2011genericdrugreport.pdf. Accessed February 20, 2013.